title: HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis.
abstract: Recurrent respiratory papillomatosis (RRP) is characterised by multiple laryngeal papillomas. Left untreated, the lesions enlarge, spread, and endanger the airway. Medical treatments are unsatisfactory, and repeated surgery remains the mainstay of therapy. RRP is caused by human papillomavirus (HPV) infection. However, since oral HPV infection is common and RRP is rare, other host and/or viral factors may contribute to pathogenesis. In an attempt to identify such factors, we have investigated 60 patients. The patients were HLA class I, II, and tumor necrosis factor TNF typed by sequence-specific primer PCR, and the results compared to those for 554 healthy controls by using Fisher's exact test. Peripheral blood mononuclear cell proliferative responses of 25 controls and 10 patients to HPV-11 L1 virus-like particles (VLP) were compared. Short-term VLP-specific T-cell lines were established, and recognition of L1 was analyzed. Finally, the L1 open reading frames of HPV isolates from four patients were sequenced. Susceptibility to RRP was associated with HLA DRB1*0301 (33 of 60 patients versus 136 of 554 controls, P < 0.0001). The three most severely affected patients were homozygous for this allele. A range of T-cell proliferative responses to HPV-11 VLP were observed in DRB1*0301-positive healthy donors which were comparable to those in DRB1*0301-negative controls. Individuals with juvenile-onset RRP also mounted a range of VLP responses, and their magnitude was negatively correlated with the clinical staging score (P = 0.012 by the Spearman rank correlation). DRB1*0301-positive patients who responded to L1 recognized the same epitope as did matched controls and produced similar cytokines. Sequencing of clinical isolates excluded the possibility that nonresponsiveness was the result of mutation(s) in L1.
authors.affiliation: Infection & Immunity, University of Wales College of Medicine, Newport, United Kingdom. viralimmunol@cf.ac.uk
authors.forename: Colin M
authors.initials: CM
authors.lastname: Gelder
authors.forename: O Martin
authors.initials: OM
authors.lastname: Williams
authors.forename: Keith W
authors.initials: KW
authors.lastname: Hart
authors.forename: Siôn
authors.initials: S
authors.lastname: Wall
authors.forename: Gareth
authors.initials: G
authors.lastname: Williams
authors.forename: Duncan
authors.initials: D
authors.lastname: Ingrams
authors.forename: Peter
authors.initials: P
authors.lastname: Bull
authors.forename: Mike
authors.initials: M
authors.lastname: Bunce
authors.forename: Ken
authors.initials: K
authors.lastname: Welsh
authors.forename: Sara E F
authors.initials: SE
authors.lastname: Marshall
authors.forename: Leszek
authors.initials: L
authors.lastname: Borysiewicz
mesh_terms: D000293:Adolescent; D000328:Adult; D036022:Capsid Proteins; D002648:Child; D002675:Child, Preschool; D005260:Female; D005802:Genes, MHC Class II; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007223:Infant; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000276:immunology; D009856:Oncogene Proteins, Viral / Q000276:immunology; D010212:Papilloma / Q000235:genetics* / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000235:genetics* / Q000276:immunology; D011110:Polymorphism, Genetic; D014412:Tumor Virus Infections / Q000235:genetics* / Q000276:immunology; D014771:Virion / Q000276:immunology
chemical_list: D036022:Capsid Proteins; C094776:L1 protein, Human papillomavirus type 11; D009856:Oncogene Proteins, Viral